A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic

Reynales, Humberto; Astudillo, Paula; Vallière, Serge De; Hatz, Christoph; Schlagenhauf, Patricia; Rath, Barbara; Velentgas, Priscilla; Fariña, Ariel; Sales-Carmona, Victor; Groth, Nicola

doi:10.1016/j.vaccine.2012.08.005

Cited by 21 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, this technology offers the potential to elicit an improved immune response through seed viruses that closely match the wild virus and also provides an option for people who are allergic to eggs [9]. Two cell-based H1pdm vaccines have been licensed and are currently used, Gelture and Optaflu [10]. Unfortunately, substitutions at residues 153–157 within HA often emerge upon passaging of the virus in cell cultures, and these substitutions are associated with reduced titers in hemagglutination inhibition (HAI) assays [11].…”

Section: Introductionmentioning

confidence: 99%

Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan

et al. 2015

View full text Add to dashboard Cite

A/Narita/1/2009 (A/N) was the first H1N1 virus from the 2009 pandemic (H1pdm) to be isolated in Japan. To better understand and predict the possible development of this virus strain, the effect of passaging A/N was investigated in Madin-Darby canine kidney cells, chicken eggs and mice. A/N that had been continuously passaged in cells, eggs, or mice obtained the ability to grow efficiently in each host. Moreover, A/N grown in mice had both a high level of pathogenicity in mice and an increased growth rate in cells and eggs. Changes in growth and pathogenicity were accompanied by amino acid substitutions in viral hemagglutinin (HA) and PB2. In addition, the adapted viruses exhibited a reduced ability to react with ferret antisera against A/N. In conclusion, prolonged passaging allowed influenza A/N to adapt to different hosts, as indicated by a high increase in proliferative capacity that was accompanied by an antigenic alteration leading to amino acid substitutions.

show abstract

Section: Introductionmentioning

confidence: 99%

Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan

et al. 2015

View full text Add to dashboard Cite

show abstract

“…121 Since the early 1990s, reports of more than 20 clinical studies involving greater than 20,000 subjects in over a dozen countries, as well as large-scale immunization programs have further confirmed the safety and immunogenicity of MDCK cell-derived influenza vaccines. As far as safety is concerned, overall AEs have been reported in up to 84% of the subjects, 112,114,116,117,[122][123][124][125] with a higher incidence in adults (60-84%) as compared to children (50-60%) and lowest (typically 15-25%, but sometimes up to 50%) in the elderly. 114,122,123,125 Total local AEs have ranged from 10% to 84%, 112,[114][115][116][117]122,124,126 again, typically higher in adults than in children, and lowest in the elderly.…”

Section: Mdck Cell-derived Influenza Vaccines: the Final Joust?mentioning

confidence: 99%

“…Mild to severe reactions requiring medical attention are observed at the most in 25% of the total local AEs, and are usually more frequent in children. 112,114,124 Systemic AEs to MDCK cell-derived influenza vaccines have been found to be lower as compared to local AEs. Total systemic AEs have ranged from 20% to 55%.…”

Section: Mdck Cell-derived Influenza Vaccines: the Final Joust?mentioning

confidence: 99%

Cell culture-based influenza vaccines: A necessary and indispensable investment for the future

Hegde

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Optaflu® (Novartis) and Flucelvax® (Novartis) were approved for individuals from the age of 18 years. Celtura® (Novartis) is a monovalent, cell culture-derived, inactivated subunit vaccine containing A(H1N1)pdm09 virus with the adjuvant MF59 [78]. Celtura® (Novartis) has been licensed in Europe.…”

Section: Recently Introduced Influenza Vaccinesmentioning

confidence: 99%

Influenza Vaccines: Unmet Needs and Recent Developments

Noh

2013

Infect Chemother

View full text Add to dashboard Cite

Influenza is a worldwide public health concern. Since the introduction of trivalent influenza vaccine in 1978, vaccination has been the primary means of prevention and control of influenza. Current influenza vaccines have moderate efficacy, good safety, and acceptable tolerability; however, they have unsatisfactory efficacy in older adults, are dependent on egg supply for production, and are time-consuming to manufacture. This review outlines the unmet medical needs of current influenza vaccines. Recent developments in influenza vaccines are also described.

show abstract

A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic

Cited by 21 publications

References 34 publications

Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan

Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan

Cell culture-based influenza vaccines: A necessary and indispensable investment for the future

Influenza Vaccines: Unmet Needs and Recent Developments

Contact Info

Product

Resources

About